VAdd image
Vesugen
LongevitySingleAlso known as: Lys-Glu-Asp
A short Khavinson-family bioregulator targeting vascular tissue, marketed for cardiovascular and circulatory support.
Half-life
—
Common dose
5 – 10 mg
Dosing frequency
Daily
Administration
Subcutaneous
How it works
Proposed mechanism involves gene-regulatory effects on vascular endothelial cells, supporting elasticity and circulatory function.
Protocol notes
Typical protocols: 5–10 mg subcutaneously daily for 10–20 days, cycled 2–3 times per year.
Reported side effects
Reportedly well-tolerated. Limited Western data.